Inclusion Criteria:

          1. Patients must have a histologically-confirmed metastatic or locally advanced solid
             tumor that has failed to respond to standard therapy, progressed despite standard
             therapy, or for which standard therapy does not exist.

          2. There is no limit on the number of prior treatment regimens.

          3. Patients must be off prior chemotherapy, hormonal therapy, or biological therapy for
             at least 4 weeks or >3 half-lives whichever comes first. Patients with prostate cancer
             may continue to receive LHRH agonist (unless orchiectomy has been performed).

          4. ECOG performance status </= 2 (Karnofsky >60%).

          5. Patients must have adequate organ and marrow function as defined below within 7 days:
             WBC >/= 2500/mm^3. Absolute neutrophil count (ANC) >/= 1,500/mm^3. Absolute lymphocyte
             count (ALC) >/= 500/mm^3. Hemoglobin >/= 9g/dl. Platelets >/= 75,000/mm^3. Creatinine
             </= 2.0 x ULN or measured CrCl of >/= 50ml/m^2/1.73 m^2. Total bilirubin </= 2.0 mg/dL
             (unless previously diagnosed with Gilbert's Syndrome). AST(SGOT)/ALT(SGPT) </= 3 times
             the institutional upper limit of normal (patients with liver involvement will be
             allowed </= 5.0 X institutional upper normal limit).

          6. Patients must have recovered from toxicity related to prior therapy to at least grade
             1 (defined by CTCAE 4.0) or baseline level. Chronic stable grade 2 peripheral
             neuropathy secondary to neurotoxicity from prior therapies may be considered on a case
             by case basis by the Principal Investigator.

          7. As the effect of these drugs on the developing human fetus is not known, women of
             child-bearing potential and men must agree to use adequate contraception (abstinence;
             hormonal or barrier method of birth control) for the study and at least 2 months after
             completion.

          8. Female patient of childbearing potential has a negative serum pregnancy test within 7
             days of study enrollment.

          9. Patients must be willing and able to review, understand, and provide written consent
             before study enrollment.

         10. Measurable disease as defined by irRC or RECIST 1.1 criteria

         11. Age >/= 18 years.

        Exclusion Criteria:

          1. Severe autoimmune disease: Patients with a history of inflammatory bowel disease
             (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as
             rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus
             Erythematosus or autoimmune vasculitis [e.g., Wegener's Granulomatosis] are excluded
             from this study. Patients with history of mild autoimmune disorders - including but
             not limited to mild psoriasis or Hashimoto's hyperthyroidism may be included at the
             discretion of the principle investigator.

          2. History of acute diverticulitis, intra-abdominal abscess, GI obstruction, abdominal
             carcinomatosis or other known risk factors for bowel perforation.

          3. Any underlying medical or psychiatric condition, which in the opinion of the
             Investigator, will make the administration of study drug hazardous or obscure the
             interpretation of AEs: e.g. a condition associated with frequent diarrhea or chronic
             skin conditions, recent surgery or colonic biopsy from which the patient has not
             recovered, or partial endocrine organ deficiencies.

          4. Current evidence of active and uncontrolled infection, NYHA Class III-IV CHF,
             documented Child's class B-C cirrhosis, active pancreatitis or uncontrolled medical
             disease which in the opinion of the investigator could compromise assessment of
             efficacy.

          5. Known human immunodeficiency virus (HIV)-positive and on highly active antiretroviral
             therapy (HAART), and/or Hepatitis B or C on treatment. Drug interactions between those
             agents and these experimental agents are wholly unknown (screening not required).

          6. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             of day 1 of therapy.

          7. Known hypersensitivity to the components of study drugs, its analogs, or drugs of
             similar chemical or biologic composition.

          8. Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to
             one month prior to or after any dose of ipilimumab).

          9. Concomitant therapy with any of the following: IL-2, interferon or other non-study
             immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other
             investigational therapies; or chronic use of systemic corticosteroids (when used in
             the management of cancers other than intracranial glioblastoma, gliosarcoma or
             anaplastic astrocytoma, or when used to treat non-cancer-related illnesses).

         10. Radiation therapy within 4 weeks of study enrollment (exception is radiotherapy
             expansion arm which requires radiation treatment within 2 week period).

         11. Pregnant and breastfeeding women are excluded from this study. Women of child-bearing
             potential and men must agree to use contraception prior to study entry and for the
             duration of study participation. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician.

         12. Use of any other concurrent investigational agents or anticancer agents including
             hormonal therapy, except in the case of prostate cancer patients who are being treated
             with LHRH agonist at the time of trial entry.

         13. Previous exposure to TLR agonist therapy.

         14. Known history of plasma cortisol and adrenocorticotropic hormone (ACTH) levels
             consistent with adrenal failure.